Mumbai-based Glenmark Pharmaceuticals has agreed to sell its gynecology operations in India and Nepal to a True North portfolio company for $16.2 million.
Chinese gene testing business AmCare Genomics Lab has raised RMB110 million ($16 m) in Series B funding led by Green Pine Capital Partners. This comes four months after the company closed an extended Series A round of RMB30 million.
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
Ankur Capital, an Indian early-stage investor focused on healthcare and agriculture technology investments, has reached a first close of INR2.4 billion ($33 million) on its second fund.
Zhiyun Health, a Chinese online healthcare services provider, has raised more than RMB1 billion ($144 million) across two rounds. It describes the investment as the largest private funding event globally in the chronic disease management space.
Transcenta Holding, a Chinese biotech company formed last year through the merger of MabSpace Bioscience and Hangzhou Just Biotherapeutics (HJB), has raised $100 million in an extended Series B funding round.
General Atlantic has led a $69 million Series D round of funding for Adagene, a Chinese drug developer with one cancer treatment currently in phase one clinical trials in China and the US.
EQT Partners has confirmed an investment of undisclosed size in Health Management International (HMI), a hospital operator with a presence in Singapore, Malaysia, and Indonesia.
CF PharmTech, a Chinese devices maker focused on respiratory health, has raised $90 million in Series E funding led by local private equity investor New Alliance Capital.
The Everstone Group has agreed to invest $50 million in Slayback Pharma, a developer of generic and specialty drugs with a presence in India and the US.
True North has invested INR5.36 billion ($74.6 million) in the biosimilars business of India-listed pharmaceuticals giant Biocon.
Geneseeq, a Chinese genetic testing company that focuses on treatments for cancer, has raised RMB800 million ($115 million) in a funding round led by state-owned China Reform Holding Corporation.
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Awak Technologies, a Singaporean start-up that makes wearable dialysis treatment devices, has raised $40 million co-led by Vickers Venture Partners and an unnamed medical technology company.
Shanghai Kechow Pharma, a Chinese small molecule targeted drug developer, has raised a $45 million Series C round led by Decheng Capital.
Lefei Sun, who helped establish and now leads General Atlantic’s healthcare and life sciences business in China, has been promoted to managing director.
EQT spent 11 years helping Chinese pharmacy chain Laobaixing evolve from large-format laggard into a focused and efficient operator that meets the needs of modern customers. It has now exited with a 7.7x return
EOC Pharma, a Chinese biotech developer focused on cancer treatments, has closed a RMB500 million ($71 million) Series C round raised from a group of local private equity investors.
Chinese cancer and autoimmune disease therapy developer Clover Biopharmaceuticals has raised a $43 million Series B round led by local VC Lapam Capital and US private equity firm Delos Capital.
China’s Loyal Valley Capital has closed its second US dollar-denominated fund at $465 million. The target was $400 million with a hard cap of $440 million.
FountainVest Partners and Primavera Capital have paid $557 million for a 24.78% stake in Chinese pharmacy chain Laobaixing. It will provide a full exit for EQT Partners.
Zenyum, a Singapore-based manufacturer of 3D-printed cosmetic dental products, has raised $13.6 million in Series A funding from RTP Global, Sequoia Capital India, TNB Aura, and Seeds Capital.
SmartScan, a Japanese medical technology supplier focused on software for diagnostics equipment, has raised a JPY1.3 billion ($10.3 million) Series A round from domestic VCs.